The role of invariant natural killer T cells in dendritic cell licensing, cross-priming, and memory CD8+ T cell generation

Frontiers in Immunology

Volumn 6, Issue JUL, 2015, Pages

  Gottschalk, Catherine ^a   Mettke, Elisabeth ^a   Kurts, Christian ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

CD8 T cells; Cross presentation; Dendritic cells; Licensing; Memory; Natural killer T cells

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18;

APOPTOSIS; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; HELPER CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLUENZA VACCINATION; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; SHORT SURVEY; TH1 TH2 BALANCE; VIRUS INFECTION;

EID: 84939218637     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00379     Document Type: Short Survey

References (141)

1. Parekh VV, Wilson MT, Van Kaer L. iNKT-cell responses to glycolipids. Crit Rev Immunol (2005) 25(3):183-213. doi: 10.1615/CritRevImmunol.v25.i3.20
2. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol (2007) 25:297-336. doi:10.1146/annurev.immunol.25.022106.141711
3. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest (2004) 114(10):1379-88. doi:10.1172/JCI23594
4. Kumar V, Delovitch TL. Different subsets of natural killer T cells may vary in their roles in health and disease. Immunology (2014) 142(3):321-36. doi:10.1111/imm.12247
5. Zeng Z, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science (1997) 277(5324):339-45. doi:10.1126/science.277.5324.339
6. Porcelli SA. The CD1 family: a third lineage of antigen-presenting molecules. Adv Immunol (1995) 59:1-98. doi:10.1016/S0065-2776(08)60629-X
7. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med (2003) 9(5):582-8. doi:10.1038/nm851
8. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med (2001) 7(9):1057-62. doi:10.1038/nm0901-1057
9. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med (2002) 195(5):637-41. doi:10.1084/jem.20011908
10. Li X, Fujio M, Imamura M, Wu D, Vasan S, Wong CH, et al. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A (2010) 107(29):13010-5. doi:10.1073/pnas.1006662107
11. Faveeuw C, Trottein F. Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines. Cancer Res (2014) 74(6):1632-8. doi:10.1158/0008-5472.CAN-13-3504
12. Carreno LJ, Kharkwal SS, Porcelli SA. Optimizing NKT cell ligands as vaccine adjuvants. Immunotherapy (2014) 6(3):309-20. doi:10.2217/imt.13.175
13. Padte NN, Li X, Tsuji M, Vasan S. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol (2011) 140(2):142-51. doi:10.1016/j.clim.2010.11.009
14. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY. Alpha-galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol (2005) 175(5):3309-17. doi:10.4049/jimmunol.175.5.3309
15. Chackerian A, Alt J, Perera V, Behar SM. Activation of NKT cells protects mice from tuberculosis. Infect Immun (2002) 70(11):6302-9. doi:10.1128/IAI.70.11.6302-6309.2002
16. Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine (2008) 26(15):1807-16. doi:10.1016/j.vaccine.2008.02.002
17. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med (2000) 192(7):921-30. doi:10.1084/jem.192.7.921
18. Kopecky-Bromberg SA, Fraser KA, Pica N, Carnero E, Moran TM, Franck RW, et al. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine (2009) 27(28):3766-74. doi:10.1016/j.vaccine.2009.03.090
19. Veldt BJ, van der Vliet HJ, von Blomberg BM, van Vlierberghe H, Gerken G, Nishi N, et al. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol (2007) 47(3):356-65. doi:10.1016/j.jhep.2007.04.018
20. Woltman AM, Ter Borg MJ, Binda RS, Sprengers D, von Blomberg BM, Scheper RJ, et al. Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled phase I/II trial. Antivir Ther (2009) 14(6):809-18. doi:10.3851/1295
21. Youn HJ, Ko SY, Lee KA, Ko HJ, Lee YS, Fujihashi K, et al. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine (2007) 25(28):5189-98. doi:10.1016/j.vaccine.2007.04.081
22. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, Hong S, Bruna-Romero O, Nakayama T, et al. Alpha-galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci U S A (2000) 97(15):8461-6. doi:10.1073/pnas.97.15.8461
23. Kawakami K, Kinjo Y, Yara S, Koguchi Y, Uezu K, Nakayama T, et al. Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect Immun (2001) 69(1):213-20. doi:10.1128/IAI.69.1.213-220.2001
24. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med (2003) 198(11):1631-41. doi:10.1084/jem.20031192
25. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med (2003) 198(2):267-79. doi:10.1084/jem.20030324
26. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med (2005) 201(9):1503-17. doi:10.1084/jem.20042592
27. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med (2002) 196(1):119-27. doi:10.1084/jem.20020092
28. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 8(12):3702-9.
29. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res (2005) 11(5):1910-7. doi:10.1158/1078-0432.CCR-04-1453
30. Kim D, Hung CF, Wu TC, Park YM. DNA vaccine with alpha-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine (2010) 28(45):7297-305. doi:10.1016/j.vaccine.2010.08.079
31. Kim YJ, Ko HJ, Kim YS, Kim DH, Kang S, Kim JM, et al. Alpha-galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity. Int J Cancer (2008) 122(12):2774-83. doi:10.1002/ijc.23444
32. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res (1995) 7(10-11):529-34.
33. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, et al. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci (2009) 100(6):1092-8. doi:10.1111/j.1349-7006.2009.01135.x
34. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, et al. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol (2009) 182(4):2492-501. doi:10.4049/jimmunol.0800126
35. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood (2004) 103(2):383-9. doi:10.1182/blood-2003-04-1155
36. Shibolet O, Alper R, Zlotogarov L, Thalenfeld B, Engelhardt D, Rabbani E, et al. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer (2003) 106(2):236-43. doi:10.1002/ijc.11201
37. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest (2004) 114(12):1800-11. doi:10.1172/JCI22046
38. Teng MW, Westwood JA, Darcy PK, Sharkey J, Tsuji M, Franck RW, et al. Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res (2007) 67(15):7495-504. doi:10.1158/0008-5472.CAN-07-0941
39. Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, et al. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother (2008) 57(3):337-45. doi:10.1007/s00262-007-0373-5
40. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med (2001) 7(9):1052-6. doi:10.1038/nm0901-1052
41. Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med (2001) 194(12):1789-99. doi:10.1084/jem.194.12.1789
42. Naumov YN, Bahjat KS, Gausling R, Abraham R, Exley MA, Koezuka Y, et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci U S A (2001) 98(24):13838-43. doi:10.1073/pnas.251531798
43. Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med (2001) 194(12):1801-11. doi:10.1084/jem.194.12.1801
44. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med (2001) 194(3):313-20. doi:10.1084/jem.194.3.313
45. Furlan R, Bergami A, Cantarella D, Brambilla E, Taniguchi M, Dellabona P, et al. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur J Immunol (2003) 33(7):1830-8. doi:10.1002/eji.200323885
46. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest (2003) 112(8):1211-22. doi:10.1172/JCI17165
47. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum (2004) 50(1):305-13. doi:10.1002/art.11489
48. Chiba A, Kaieda S, Oki S, Yamamura T, Miyake S. The involvement of V(alpha)14 natural killer T cells in the pathogenesis of arthritis in murine models. Arthritis Rheum (2005) 52(6):1941-8. doi:10.1002/art.21056
49. Kim HY, Kim HJ, Min HS, Kim S, Park WS, Park SH, et al. NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor beta1 production. J Exp Med (2005) 201(1):41-7. doi:10.1084/jem.20041400
50. Kojo S, Seino K, Harada M, Watarai H, Wakao H, Uchida T, et al. Induction of regulatory properties in dendritic cells by Valpha14 NKT cells. J Immunol (2005) 175(6):3648-55. doi:10.4049/jimmunol.175.6.3648
51. Major AS, Singh RR, Joyce S, Van Kaer L. The role of invariant natural killer T cells in lupus and atherogenesis. Immunol Res (2006) 34(1):49-66. doi:10.1385/IR:34:1:49
52. Yang JQ, Wen X, Liu H, Folayan G, Dong X, Zhou M, et al. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. Arthritis Rheum (2007) 56(4):1219-33. doi:10.1002/art.22490
53. Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, Li X, et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol (2011) 12(10):966-74. doi:10.1038/ni.2096
54. Chang YJ, Kim HY, Albacker LA, Lee HH, Baumgarth N, Akira S, et al. Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. J Clin Invest (2011) 121(1):57-69. doi:10.1172/JCI44845
55. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, Ho DD, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature (2005) 434(7032):520-5. doi:10.1038/nature03407
56. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C III, Zhou D, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature (2005) 434(7032):525-9. doi:10.1038/nature03408
57. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, Benhnia MR, et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol (2006) 7(9):978-86. doi:10.1038/ni1380
58. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science (1997) 278(5343):1626-9. doi:10.1126/science.278.5343.1626
59. Mallevaey T, Selvanantham T. Strategy of lipid recognition by invariant natural killer T cells: 'one for all and all for one'. Immunology (2012) 136(3):273-82. doi:10.1111/j.1365-2567.2012.03580.x
60. Oki S, Miyake S. Invariant natural killer T (iNKT) cells in asthma: a novel insight into the pathogenesis of asthma and the therapeutic implication of glycolipid ligands for allergic diseases. Allergol Int (2007) 56(1):7-14. doi:10.2332/allergolint.R-06-137
61. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol (2003) 4(12):1230-7. doi:10.1038/ni1002
62. Wesley JD, Tessmer MS, Chaukos D, Brossay L. NK cell-like behavior of Valpha14i NK T cells during MCMV infection. PLoS Pathog (2008) 4(7):e1000106. doi:10.1371/journal.ppat.1000106
63. Tyznik AJ, Tupin E, Nagarajan NA, Her MJ, Benedict CA, Kronenberg M. Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J Immunol (2008) 181(7):4452-6. doi:10.4049/jimmunol.181.7.4452
64. Salio M, Speak AO, Shepherd D, Polzella P, Illarionov PA, Veerapen N, et al. Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc Natl Acad Sci U S A (2007) 104(51):20490-5. doi:10.1073/pnas.0710145104
65. Paget C, Mallevaey T, Speak AO, Torres D, Fontaine J, Sheehan KC, et al. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity (2007) 27(4):597-609. doi:10.1016/j.immuni.2007.08.017
66. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG, et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 202(9):1279-88. doi:10.1084/jem.20050953
67. Lee YJ, Holzapfel KL, Zhu J, Jameson SC, Hogquist KA. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol (2013) 14(11):1146-54. doi:10.1038/ni.2731
68. Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB, et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med (2007) 204(5):995-1001. doi:10.1084/jem.20061551
69. Li S, Joseph C, Becourt C, Klibi J, Luce S, Dubois-Laforgue D, et al. Potential role of IL-17-producing iNKT cells in type 1 diabetes. PLoS One (2014) 9(4):e96151. doi:10.1371/journal.pone.0096151
70. Webster KE, Kim HO, Kyparissoudis K, Corpuz TM, Pinget GV, Uldrich AP, et al. IL-17-producing NKT cells depend exclusively on IL-7 for homeostasis and survival. Mucosal Immunol (2014) 7(5):1058-67. doi:10.1038/mi.2013.122
71. Monteiro M, Almeida CF, Agua-Doce A, Graca L. Induced IL-17-producing invariant NKT cells require activation in presence of TGF-beta and IL-1beta. J Immunol (2013) 190(2):805-11. doi:10.4049/jimmunol.1201010
72. Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, et al. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity (2012) 37(3):574-87. doi:10.1016/j.immuni.2012.06.016
73. Schoenberger SP, van der Voort EI, Krietemeijer GM, Offringa R, Melief CJ, Toes RE. Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells. J Immunol (1998) 161(8):3808-12.
74. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature (1999) 398(6722):77-80. doi:10.1038/18038
75. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med (2000) 192(12):1685-96. doi:10.1084/jem.192.12.1685
76. Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat Rev Immunol (2010) 10(6):403-14. doi:10.1038/nri2780
77. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol (2004) 5(11):1143-8. doi:10.1038/ni1129
78. Lanzavecchia A. Immunology. Licence to kill. Nature (1998) 393(6684):413-4. doi:10.1038/30845
79. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med (1997) 186(1):65-70. doi:10.1084/jem.186.1.65
80. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 393(6684):474-8. doi:10.1038/30989
81. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 393(6684):480-3. doi:10.1038/31002
82. Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune responses. Science (2001) 293(5528):253-6. doi:10.1126/science.1062060
83. Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol (2003) 3(5):371-82. doi:10.1038/nri1086
84. Geijtenbeek TB, van Vliet SJ, Engering A, t Hart BA, van Kooyk Y. Self-and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol (2004) 22:33-54. doi:10.1146/annurev.immunol.22.012703.104558
85. Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E, et al. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity (2005) 22(4):507-17. doi:10.1016/j.immuni.2005.03.004
86. Miga AJ, Masters SR, Durell BG, Gonzalez M, Jenkins MK, Maliszewski C, et al. Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions. Eur J Immunol (2001) 31(3):959-65. doi:10.1002/1521-4141(200103)31:3<959::AID-IMMU959>3.0.CO;2-A
87. Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol (2007) 7(12):929-41. doi:10.1038/nri2191
88. Gelin C, Sloma I, Charron D, Mooney N. Regulation of MHC II and CD1 antigen presentation: from ubiquity to security. J Leukoc Biol (2009) 85(2):215-24. doi:10.1189/jlb.0308206
89. Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M, et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol (2000) 12(7):987-94. doi:10.1093/intimm/12.7.987
90. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol (2003) 171(10):5140-7. doi:10.4049/jimmunol.171.10.5140
91. Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K, Panzer U, et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol (2010) 11(4):313-20. doi:10.1038/ni.1848
92. Shimizu K, Asakura M, Shinga J, Sato Y, Kitahara S, Hoshino K, et al. Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction. J Immunol (2013) 190(11):5609-19. doi:10.4049/jimmunol.1300033
93. Liu TY, Uemura Y, Suzuki M, Narita Y, Hirata S, Ohyama H, et al. Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. Eur J Immunol (2008) 38(4):1012-23. doi:10.1002/eji.200737838
94. Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt LA, McKenzie BS, et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1-NKT cell population. Proc Natl Acad Sci U S A (2008) 105(32):11287-92. doi:10.1073/pnas.0801631105
95. Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli M, et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 104(10):3984-9. doi:10.1073/pnas.0700191104
96. Guillonneau C, Mintern JD, Hubert FX, Hurt AC, Besra GS, Porcelli S, et al. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci U S A (2009) 106(9):3330-5. doi:10.1073/pnas.0813309106
97. Reilly EC, Thompson EA, Aspeslagh S, Wands JR, Elewaut D, Brossay L. Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection. PLoS One (2012) 7(5):e37991. doi:10.1371/journal.pone.0037991
98. Mars LT, Mas M, Beaudoin L, Bauer J, Leite-de-Moraes M, Lehuen A, et al. Invariant NKT cells regulate the CD8 T cell response during Theiler's virus infection. PLoS One (2014) 9(1):e87717. doi:10.1371/journal.pone.0087717
99. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med (2002) 195(5):617-24. doi:10.1084/jem.20011889
100. Jennings SR, Bonneau RH, Smith PM, Wolcott RM, Chervenak R. CD4-positive T lymphocytes are required for the generation of the primary but not the secondary CD8-positive cytolytic T lymphocyte response to herpes simplex virus in C57BL/6 mice. Cell Immunol (1991) 133(1):234-52. doi:10.1016/0008-8749(91)90194-G
101. Riberdy JM, Christensen JP, Branum K, Doherty PC. Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice. J Virol (2000) 74(20):9762-5. doi:10.1128/JVI.74.20.9762-9765.2000
102. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 421(6925):852-6. doi:10.1038/nature01441
103. Husmann LA, Bevan MJ. Cooperation between helper T cells and cytotoxic T lymphocyte precursors. Ann N Y Acad Sci (1988) 532:158-69. doi:10.1111/j.1749-6632.1988.tb36335.x
104. Guerder S, Matzinger P. A fail-safe mechanism for maintaining self-tolerance. J Exp Med (1992) 176(2):553-64. doi:10.1084/jem.176.2.553
105. Di Rosa F, Matzinger P. Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells. J Exp Med (1996) 183(5):2153-63. doi:10.1084/jem.183.5.2153
106. Bourgeois C, Veiga-Fernandes H, Joret AM, Rocha B, Tanchot C. CD8 lethargy in the absence of CD4 help. Eur J Immunol (2002) 32(8):2199-207. doi:10.1002/1521-4141(200208)32:8<2199::AID-IMMU2199>3.0.CO;2-L
107. Marzo AL, Vezys V, Klonowski KD, Lee SJ, Muralimohan G, Moore M, et al. Fully functional memory CD8 T cells in the absence of CD4 T cells. J Immunol (2004) 173(2):969-75. doi:10.4049/jimmunol.173.2.969
108. Serbina NV, Lazarevic V, Flynn JL. CD4(+) T cells are required for the development of cytotoxic CD8(+) T cells during Mycobacterium tuberculosis infection. J Immunol (2001) 167(12):6991-7000. doi:10.4049/jimmunol.167.12.6991
109. Tyznik AJ, Sun JC, Bevan MJ. The CD8 population in CD4-deficient mice is heavily contaminated with MHC class II-restricted T cells. J Exp Med (2004) 199(4):559-65. doi:10.1084/jem.20031961
110. Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity (2011) 35(2):161-8. doi:10.1016/j.immuni.2011.07.010
111. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev (2006) 211:81-92. doi:10.1111/j.0105-2896.2006.00382.x
112. Parish IA, Kaech SM. Diversity in CD8(+) T cell differentiation. Curr Opin Immunol (2009) 21(3):291-7. doi:10.1016/j.coi.2009.05.008
113. Stemberger C, Neuenhahn M, Buchholz VR, Busch DH. Origin of CD8+ effector and memory T cell subsets. Cell Mol Immunol (2007) 4(6):399-405.
114. Gerlach C, van Heijst JW, Swart E, Sie D, Armstrong N, Kerkhoven RM, et al. One naive T cell, multiple fates in CD8+ T cell differentiation. J Exp Med (2010) 207(6):1235-46. doi:10.1084/jem.20091175
115. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol (2012) 12(11):749-61. doi:10.1038/nri3307
116. Curtsinger JM, Johnson CM, Mescher MF. CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J Immunol (2003) 171(10):5165-71. doi:10.4049/jimmunol.171.10.5165
117. Pearce EL, Shen H. Generation of CD8 T cell memory is regulated by IL-12. J Immunol (2007) 179(4):2074-81. doi:10.4049/jimmunol.179.4.2074
118. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity (2010) 32(1):79-90. doi:10.1016/j.immuni.2009.11.012
119. Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res (2011) 317(5):620-31. doi:10.1016/j.yexcr.2010.12.017
120. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature (2009) 462(7272):510-3. doi:10.1038/nature08511
121. Kastenmuller W, Brandes M, Wang Z, Herz J, Egen JG, Germain RN. Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8+ T cell responses in the lymph node. Immunity (2013) 38(3):502-13. doi:10.1016/j.immuni.2012.11.012
122. Bedoui S, Gebhardt T. Interaction between dendritic cells and T cells during peripheral virus infections: a role for antigen presentation beyond lymphoid organs?. Curr Opin Immunol (2011) 23(1):124-30. doi:10.1016/j.coi.2010.11.001
123. McGill J, Legge KL. Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection. J Immunol (2009) 183(7):4177-81. doi:10.4049/jimmunol.0901109
124. Laidlaw BJ, Zhang N, Marshall HD, Staron MM, Guan T, Hu Y, et al. CD4+ T cell help guides formation of CD103+ lung-resident memory CD8+ T cells during influenza viral infection. Immunity (2014) 41(4):633-45. doi:10.1016/j.immuni.2014.09.007
125. Kurachi M, Kurachi J, Suenaga F, Tsukui T, Abe J, Ueha S, et al. Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration. J Exp Med (2011) 208(8):1605-20. doi:10.1084/jem.20102101
126. Kohlmeier JE, Reiley WW, Perona-Wright G, Freeman ML, Yager EJ, Connor LM, et al. Inflammatory chemokine receptors regulate CD8(+) T cell contraction and memory generation following infection. J Exp Med (2011) 208(8):1621-34. doi:10.1084/jem.20102110
127. Tomiyama H, Matsuda T, Takiguchi M. Differentiation of human CD8(+) T cells from a memory to memory/effector phenotype. J Immunol (2002) 168(11):5538-50. doi:10.4049/jimmunol.168.11.5538
128. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 22:745-63. doi:10.1146/annurev.immunol.22.012703.104702
129. Tomiyama H, Takata H, Matsuda T, Takiguchi M. Phenotypic classification of human CD8+ T cells reflecting their function: inverse correlation between quantitative expression of CD27 and cytotoxic effector function. Eur J Immunol (2004) 34(4):999-1010. doi:10.1002/eji.200324478
130. Bousso P, Albert ML. Signal 0 for guided priming of CTLs: NKT cells do it too. Nat Immunol (2010) 11(4):284-6. doi:10.1038/ni0410-284
131. Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CGA. Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol (2000) 115(4):640-6. doi:10.1046/j.1523-1747.2000.00115.x
132. Nakatani T, Kaburagi Y, Shimada Y, Inaoki M, Takehara K, Mukaida N, et al. CCR4 memory CD4+ T lymphocytes are increased in peripheral blood and lesional skin from patients with atopic dermatitis. J Allergy Clin Immunol (2001) 107(2):353-8. doi:10.1067/mai.2001.112601
133. Kusumoto M, Xu B, Shi M, Matsuyama T, Aoyama K, Takeuchi T. Expression of chemokine receptor CCR4 and its ligands (CCL17 and CCL22) in murine contact hypersensitivity. J Interferon Cytokine Res (2007) 27(11):901-10. doi:10.1089/jir.2006.0064
134. Gehad A, Al-Banna NA, Vaci M, Issekutz AC, Mohan K, Latta M, et al. Differing requirements for CCR4, E-selectin, and alpha4beta1 for the migration of memory CD4 and activated T cells to dermal inflammation. J Immunol (2012) 189(1):337-46. doi:10.4049/jimmunol.1102315
135. Oo YH, Shetty S, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. Dig Dis (2010) 28(1):31-44. doi:10.1159/000282062
136. Teraki Y, Miyake A, Takebayashi R, Shiohara T. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin Exp Dermatol (2004) 29(6):658-63. doi:10.1111/j.1365-2230.2004.01638.x
137. Wenzel J, Henze S, Worenkamper E, Basner-Tschakarjan E, Sokolowska-Wojdylo M, Steitz J, et al. Role of the chemokine receptor CCR4 and its ligand thymus-and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. J Invest Dermatol (2005) 124(6):1241-8. doi:10.1111/j.0022-202X.2005.23755.x
138. Seneviratne SL, Black AP, Jones L, Bailey AS, Ogg GS. The role of skin-homing T cells in extrinsic atopic dermatitis. QJM (2007) 100(1):19-27. doi:10.1093/qjmed/hcl132
139. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood (2003) 101(11):4260-6. doi:10.1182/blood-2002-11-3577
140. Le Gros G, Erard F. Non-cytotoxic, IL-4, IL-5, IL-10 producing CD8+ T cells: their activation and effector functions. Curr Opin Immunol (1994) 6(3):453-7. doi:10.1016/0952-7915(94)90127-9
141. Kondo T, Takiguchi M. Human memory CCR4+CD8+ T cell subset has the ability to produce multiple cytokines. Int Immunol (2009) 21(5):523-32. doi:10.1093/intimm/dxp019